{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:55:42Z","timestamp":1780469742350,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jogoh.2024.102783","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T15:52:19Z","timestamp":1711641139000},"page":"102783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-1544","authenticated-orcid":false,"given":"Oadi N.","family":"Shrateh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal Ashok","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areesha","family":"Jawed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hamza","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hammad Ur Rehman","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashhour","family":"Naasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jogoh.2024.102783_bib0001","article-title":"Technical report: breastfeeding and the use of human milk","volume":"150","author":"Meek","year":"2022","journal-title":"Pediatrics"},{"issue":"2 Pt 1","key":"10.1016\/j.jogoh.2024.102783_bib0002","first-page":"479","article-title":"ACOG committee opinion No. 361: breastfeeding: maternal and infant aspects","volume":"109","author":"Women","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2024.102783_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/TCRM.S96298","article-title":"A retrospective drug use evaluation of cabergoline for lactation inhibition at a tertiary care teaching hospital in Qatar","author":"AlSaad","year":"2016","journal-title":"Ther Clin Risk Manag"},{"issue":"9","key":"10.1016\/j.jogoh.2024.102783_bib0004","article-title":"Treatments for suppression of lactation","author":"Oladapo","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.jogoh.2024.102783_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0091-2182(89)90124-9","article-title":"Leaking: a problem of lactation","volume":"34","author":"Morse","year":"1989","journal-title":"J Nurse Midwifery"},{"issue":"6","key":"10.1016\/j.jogoh.2024.102783_bib0006","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0002-9378(98)70013-4","article-title":"Treatment for lactation suppression: little progress in one hundred years","volume":"179","author":"Spitz","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"5627","key":"10.1016\/j.jogoh.2024.102783_bib0007","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/bmj.4.5627.387","article-title":"Inhibition of lactation by oestrogens","volume":"4","author":"Llewellyn-Jones","year":"1968","journal-title":"Br Med J"},{"issue":"12 Suppl","key":"10.1016\/j.jogoh.2024.102783_bib0008","first-page":"1105","article-title":"Dopamine agonist therapy in hyperprolactinemia","volume":"44","author":"Webster","year":"1999","journal-title":"J Reprod Med"},{"key":"10.1016\/j.jogoh.2024.102783_bib0009","unstructured":"(SmPC), H.P. Bromocriptine 2.5mg Tablets. 2020 09\/12\/2023]; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1202\/smpc."},{"key":"10.1016\/j.jogoh.2024.102783_bib0010","unstructured":"(SmPC), H.P. Dostinex Tablets. 2020 09\/12\/2023]; Available from: https:\/\/www.medicines.org.uk\/emc\/product\/1691\/smpc."},{"issue":"52","key":"10.1016\/j.jogoh.2024.102783_bib0011","first-page":"2155","article-title":"Suppression of lactation with high doses of pyridoxine","volume":"49","author":"Marcus","year":"1975","journal-title":"S Afr Med J"},{"issue":"1","key":"10.1016\/j.jogoh.2024.102783_bib0012","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1471-0528.1976.tb00730.x","article-title":"The failure of pyridoxine in suppression of puerperal lactation","volume":"83","author":"MacDonald","year":"1976","journal-title":"BJOG"},{"issue":"4","key":"10.1016\/j.jogoh.2024.102783_bib0013","doi-asserted-by":"crossref","first-page":"W-65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.jogoh.2024.102783_bib0014","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"2019","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jogoh.2024.102783_bib0015","unstructured":"Cochrane. 2, R. A revised Cochrane risk-of-bias tool for randomized trials. 2023 09\/12\/2023]; Available from: https:\/\/methods.cochrane.org\/bias\/resources\/rob-2-revised-cochrane-risk-bias-tool-randomized-trials."},{"key":"10.1016\/j.jogoh.2024.102783_bib0016","unstructured":"Cochrane. Risk Of Bias In Non-Randomized Studies - of Interventions (ROBINS-I). 2023 09\/12\/2023]; Available from: https:\/\/methods.cochrane.org\/bias\/risk-bias-non-randomized-studies-interventions."},{"issue":"5","key":"10.1016\/j.jogoh.2024.102783_bib0017","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1471-0528.1976.tb00848.x","article-title":"The influence of pyridoxine on prolactin secretion and milk production in women","volume":"83","author":"Canales","year":"1976","journal-title":"BJOG"},{"issue":"22","key":"10.1016\/j.jogoh.2024.102783_bib0018","first-page":"900","article-title":"Inhibition of puerperal lactation-a comparative study of bromocriptine and pyridoxine","volume":"57","author":"Boes","year":"1980","journal-title":"S Afr Med J"},{"key":"10.1016\/j.jogoh.2024.102783_bib0019","article-title":"The efficiency of cabergoline vs pyridoxine for lactation inhibition\u2014A randomized controlled trial","author":"Dayan-Schwartz","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jogoh.2024.102783_bib0020","unstructured":"Fawole, O.T.O. Treatments for suppression of lactation. 2012 03\/24\/2024]; Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD005937.pub3\/full?highlightAbstract=lactat%7Clactation."},{"key":"10.1016\/j.jogoh.2024.102783_bib0021","unstructured":"Hamlyn, B., et al., Infant Feeding Report 2000: a Survey Conducted on Behalf of the Department of Health, the Scottish Executive, the National Assembly for Wales and the Department of Health Social Services and Public Safety in Northern Ireland. 2002: Stationery Office."},{"issue":"5638","key":"10.1016\/j.jogoh.2024.102783_bib0022","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/bmj.1.5638.255","article-title":"Stilboestrol inhibition of lactation","volume":"1","author":"Senior","year":"1969","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.jogoh.2024.102783_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-197510020-00003","article-title":"Inhibition of lactation","volume":"10","author":"Llewellyn-Jones","year":"1975","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.jogoh.2024.102783_bib0024","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000499470","article-title":"Dopamine agonists: from the 1970s to today","volume":"109","author":"Auriemma","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"5622","key":"10.1016\/j.jogoh.2024.102783_bib0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.4.5622.19","article-title":"Puerperal thromboembolism in relation to the inhibition of lactation by oestrogen therapy","volume":"4","author":"Jeffcoate","year":"1968","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.jogoh.2024.102783_bib0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/00016347709162122","article-title":"Stilbestrol administration in the puerperium and its effect on the prolactin excretion of non-lactating patients","volume":"56","author":"David","year":"1977","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.jogoh.2024.102783_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11096-005-3663-z","article-title":"The history of DES, lessons to be learned","volume":"27","author":"Veurink","year":"2005","journal-title":"Pharmacy World Sci"},{"issue":"3","key":"10.1016\/j.jogoh.2024.102783_bib0028","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1479-828X.1979.tb02744.x","article-title":"Inhibition of puerperal lactation evaluation of bromocriptine and placebo","volume":"19","author":"Bhardwaj","year":"1979","journal-title":"Australian New Zealand J Obstet Gynaecol"},{"issue":"4","key":"10.1016\/j.jogoh.2024.102783_bib0029","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00016347709154987","article-title":"Inhibition of puerperal lactation: a double blind study of bromocriptine and placebo","volume":"56","author":"Dewhurst","year":"1977","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"4","key":"10.1016\/j.jogoh.2024.102783_bib0030","first-page":"464","article-title":"Bromocriptine mesylate for prevention of postpartum lactation","volume":"57","author":"DUCHESNE","year":"1981","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.jogoh.2024.102783_bib0031","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1471-0528.1991.tb13392.x","article-title":"Lactation inhibition by the dopamine agonist CV 205\u2013502","volume":"98","author":"Van Der Heijden","year":"1991","journal-title":"BJOG"},{"key":"10.1016\/j.jogoh.2024.102783_bib0032","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1136\/bmj.302.6789.1367","article-title":"Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study","volume":"302","author":"BMJ","year":"1991","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jogoh.2024.102783_bib0033","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000293109","article-title":"Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery","volume":"31","author":"Giorda","year":"1991","journal-title":"Gynecol Obstet Invest"},{"issue":"3 Pt 1","key":"10.1016\/j.jogoh.2024.102783_bib0034","first-page":"311","article-title":"Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline","volume":"71","author":"Melis","year":"1988","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.jogoh.2024.102783_bib0035","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/jcpt.12526","article-title":"Is pyridoxine effective and safe for post-partum lactation inhibition? A systematic review","volume":"42","author":"AlSaad","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"7.58","key":"10.1016\/j.jogoh.2024.102783_bib0036","first-page":"15","article-title":"The role of vitamin B6 in reducing serum prolactin in comparison to cabergoline","volume":"28","author":"Witwit","year":"2019","journal-title":"Age"},{"issue":"8","key":"10.1016\/j.jogoh.2024.102783_bib0037","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1471-0528.1973.tb16057.x","article-title":"An antilactogenic effect of pyridoxine","volume":"80","author":"Foukas","year":"1973","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.jogoh.2024.102783_bib0038","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jogc.2019.03.014","article-title":"Safety of cabergoline for postpartum lactation inhibition or suppression: a systematic review","volume":"42","author":"Harris","year":"2020","journal-title":"J Obstet Gynaecol Canada"},{"key":"10.1016\/j.jogoh.2024.102783_bib0039","first-page":"10.1097","article-title":"Cabergoline for lactation inhibition after second-trimester abortion or pregnancy loss: a randomized controlled trial","author":"Henkel","year":"2022","journal-title":"Obstet Gynecol"},{"issue":"9","key":"10.1016\/j.jogoh.2024.102783_bib0040","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/1471-0528.13352","article-title":"Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey","volume":"122","author":"Bernard","year":"2015","journal-title":"BJOG"},{"key":"10.1016\/j.jogoh.2024.102783_bib0041","series-title":"Fundamental & clinical pharmacology","article-title":"Pharmacovigilance of ergot derivatives used for lactation inhibition","author":"Mirkou","year":"2010"},{"key":"10.1016\/j.jogoh.2024.102783_bib0042","unstructured":"Harry Schiller. 60 FR 3404 - Sandoz Pharmaceuticals Corp.; Bromocriptine Mesylate (Parlodel); Withdrawal of Approval of the Indication for the Prevention of Physiological Lactation. 1995 09\/12\/2023]; Available from: https:\/\/www.govinfo.gov\/app\/details\/FR-1995-01-17\/95-1074."},{"key":"10.1016\/j.jogoh.2024.102783_bib0043","series-title":"Fundamental & clinical pharmacology","article-title":"Safety of cabergoline in lactation inhibition during the puerperal period","author":"Chouchana","year":"2017"}],"container-title":["Journal of Gynecology Obstetrics and Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784724000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468784724000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T09:24:26Z","timestamp":1716629066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468784724000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2468784724000618"],"URL":"https:\/\/doi.org\/10.1016\/j.jogoh.2024.102783","relation":{},"ISSN":["2468-7847"],"issn-type":[{"value":"2468-7847","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing pyridoxine with dopaminergic agonists (cabergoline and bromocriptine): Unveiling the strategy for lactation inhibition - A systematic review of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Gynecology Obstetrics and Human Reproduction","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jogoh.2024.102783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"102783"}}